189 related articles for article (PubMed ID: 36977736)
1. Comprehensive pan-cancer analysis of STAT3 as a prognostic and immunological biomarker.
He Z; Song B; Zhu M; Liu J
Sci Rep; 2023 Mar; 13(1):5069. PubMed ID: 36977736
[TBL] [Abstract][Full Text] [Related]
2. PHF5A is a potential diagnostic, prognostic, and immunological biomarker in pan-cancer.
Ding N; Li M; Zhao X
Sci Rep; 2023 Oct; 13(1):17521. PubMed ID: 37845358
[TBL] [Abstract][Full Text] [Related]
3. Prognostic role of STAT3 in solid tumors: a systematic review and meta-analysis.
Wu P; Wu D; Zhao L; Huang L; Shen G; Huang J; Chai Y
Oncotarget; 2016 Apr; 7(15):19863-83. PubMed ID: 26959884
[TBL] [Abstract][Full Text] [Related]
4. Cell Division Cycle-Associated Protein 3 (CDCA3) Is a Potential Biomarker for Clinical Prognosis and Immunotherapy in Pan-Cancer.
Xu Y; Shen M; Peng Y; Liu L; Tang L; Yang T; Pu D; Tan W; Zhang W; Liu S
Biomed Res Int; 2022; 2022():4632453. PubMed ID: 36082153
[TBL] [Abstract][Full Text] [Related]
5. A comprehensive analysis of PANoptosome to prognosis and immunotherapy response in pan-cancer.
Zhuang L; Sun Q; Huang S; Hu L; Chen Q
Sci Rep; 2023 Mar; 13(1):3877. PubMed ID: 36890219
[TBL] [Abstract][Full Text] [Related]
6. KIF11 As a Potential Pan-Cancer Immunological Biomarker Encompassing the Disease Staging, Prognoses, Tumor Microenvironment, and Therapeutic Responses.
Guo X; Zhou L; Wu Y; Li J
Oxid Med Cell Longev; 2022; 2022():2764940. PubMed ID: 36742345
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive analysis of PILRΑ's association with the prognosis, tumor immune infiltration, and immunotherapy in pan-cancer.
Li Q; Yang Z; He X; Yang X
Sci Rep; 2023 Aug; 13(1):14334. PubMed ID: 37652967
[TBL] [Abstract][Full Text] [Related]
8. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
9. Systematic Pan-Cancer Analysis of KLRB1 with Prognostic Value and Immunological Activity across Human Tumors.
Cheng X; Cao Y; Wang X; Cheng L; Liu Y; Lei J; Peng W; Shi D
J Immunol Res; 2022; 2022():5254911. PubMed ID: 35028320
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive bioinformatics analysis of ribonucleoside diphosphate reductase subunit M2(RRM2) gene correlates with prognosis and tumor immunotherapy in pan-cancer.
Wu L; Yin L; Ma L; Yang J; Yang F; Sun B; Nianzeng X
Aging (Albany NY); 2022 Oct; 14(19):7890-7905. PubMed ID: 36202136
[TBL] [Abstract][Full Text] [Related]
11. Systematic analysis identifies XRCC4 as a potential immunological and prognostic biomarker associated with pan-cancer.
Yu Y; Sun Y; Li Z; Li J; Tian D
BMC Bioinformatics; 2023 Feb; 24(1):44. PubMed ID: 36765282
[TBL] [Abstract][Full Text] [Related]
12. Pan-cancer analysis of the prognostic and immunological role of SNX29: a potential target for survival and immunotherapy.
Xu C; Li F; Liu Z; Yan C; Xiao J
BMC Med Genomics; 2023 Feb; 16(1):34. PubMed ID: 36829159
[TBL] [Abstract][Full Text] [Related]
13. An integrated pan-cancer analysis of TFAP4 aberrations and the potential clinical implications for cancer immunity.
Liu JN; Kong XS; Sun P; Wang R; Li W; Chen QF
J Cell Mol Med; 2021 Feb; 25(4):2082-2097. PubMed ID: 33373169
[TBL] [Abstract][Full Text] [Related]
14. Pan-Cancer Analysis of PDIA3: Identifying It as a Potential Biomarker for Tumor Prognosis and Immunotherapy.
Zhang J; Wang K; Hainisayimu T; Li H
Oxid Med Cell Longev; 2022; 2022():9614819. PubMed ID: 36046686
[TBL] [Abstract][Full Text] [Related]
15. ORC6, a novel prognostic biomarker, correlates with T regulatory cell infiltration in prostate adenocarcinoma: a pan-cancer analysis.
Lin Y; Zhang Y; Tuo Z; Gao L; Ding D; Bi L; Yu D; Lv Z; Wang J; Chen X
BMC Cancer; 2023 Mar; 23(1):285. PubMed ID: 36978046
[TBL] [Abstract][Full Text] [Related]
16. Mitochondrial GRIM-19 as a potential therapeutic target for STAT3-dependent carcinogenesis of gastric cancer.
Huang Y; Yang M; Hu H; Zhao X; Bao L; Huang D; Song L; Li Y
Oncotarget; 2016 Jul; 7(27):41404-41420. PubMed ID: 27167343
[TBL] [Abstract][Full Text] [Related]
17. Multi-omics analysis of N6-methyladenosine reader IGF2BP3 as a promising biomarker in pan-cancer.
Chen P; Xu J; Cui Z; Wu S; Xie T; Zhang X
Front Immunol; 2023; 14():1071675. PubMed ID: 36761737
[TBL] [Abstract][Full Text] [Related]
18. Pan-cancer analysis: predictive role of TAP1 in cancer prognosis and response to immunotherapy.
Tu Z; Li K; Ji Q; Huang Y; Lv S; Li J; Wu L; Huang K; Zhu X
BMC Cancer; 2023 Feb; 23(1):133. PubMed ID: 36759763
[TBL] [Abstract][Full Text] [Related]
19. Pan-Cancer Analysis Shows That ALKBH5 Is a Potential Prognostic and Immunotherapeutic Biomarker for Multiple Cancer Types Including Gliomas.
Wei C; Wang B; Peng D; Zhang X; Li Z; Luo L; He Y; Liang H; Du X; Li S; Zhang S; Zhang Z; Han L; Zhang J
Front Immunol; 2022; 13():849592. PubMed ID: 35444654
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive Analysis of FASN in Tumor Immune Infiltration and Prognostic Value for Immunotherapy and Promoter DNA Methylation.
Zhang M; Yu L; Sun Y; Hao L; Bai J; Yuan X; Wu R; Hong M; Liu P; Duan X; Wang C
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
